[go: up one dir, main page]

NO20000414L - Benzyl compounds that inhibit leukocyte adhesion mediated by VLA-4 - Google Patents

Benzyl compounds that inhibit leukocyte adhesion mediated by VLA-4

Info

Publication number
NO20000414L
NO20000414L NO20000414A NO20000414A NO20000414L NO 20000414 L NO20000414 L NO 20000414L NO 20000414 A NO20000414 A NO 20000414A NO 20000414 A NO20000414 A NO 20000414A NO 20000414 L NO20000414 L NO 20000414L
Authority
NO
Norway
Prior art keywords
vla
compounds
leukocyte adhesion
adhesion mediated
inhibit leukocyte
Prior art date
Application number
NO20000414A
Other languages
Norwegian (no)
Other versions
NO20000414D0 (en
Inventor
Eugene D Thorsett
Christopher M Semko
Michael A Pleiss
Louis John Lombardo
Andrei W Konradi
Francine S Grant
Darren B Dressen
Michael S Dappen
Original Assignee
Elan Pharm Inc
American Home Prod
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Elan Pharm Inc, American Home Prod filed Critical Elan Pharm Inc
Publication of NO20000414D0 publication Critical patent/NO20000414D0/en
Publication of NO20000414L publication Critical patent/NO20000414L/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • C07K5/06165—Dipeptides with the first amino acid being heterocyclic and Pro-amino acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Det er beskrevet forbindelser som binder VLA-4. Noen av disse forbindelsene inhiberer også leukocytt-adhesjon og spesielt leukocytt-adhesjon mediert av VLA-4. Slike forbindelser er nyttige for behandling av inflammatoriske sykdommer i en pattedyrpasient, for eksempel et menneske, hvori sykdommen for eksempel kan være astma, Alzheimer's sykdom, aterosklerose, AIDS-demens, diabetes, inflammatorisk tarmsykdom, leddgikt, vevstransplantasjon, tumor- metastase og myokardial ischemi. Forbindelsene kan også bli administrert for behandling av inflammatoriske hjernesykdommer så som multippel sklerose.Compounds that bind VLA-4 are described. Some of these compounds also inhibit leukocyte adhesion and especially leukocyte adhesion mediated by VLA-4. Such compounds are useful for the treatment of inflammatory diseases in a mammalian patient, for example a human, in which the disease may be, for example, asthma, Alzheimer's disease, atherosclerosis, AIDS dementia, diabetes, inflammatory bowel disease, arthritis, tissue transplantation, tumor metastasis and myocardial ischemia. . The compounds may also be administered for the treatment of inflammatory brain diseases such as multiple sclerosis.

NO20000414A 1997-07-31 2000-01-27 Benzyl compounds that inhibit leukocyte adhesion mediated by VLA-4 NO20000414L (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US90358597A 1997-07-31 1997-07-31
PCT/US1998/015327 WO1999006436A1 (en) 1997-07-31 1998-07-31 Benzyl compounds which inhibit leukocyte adhesion mediated by vla-4

Publications (2)

Publication Number Publication Date
NO20000414D0 NO20000414D0 (en) 2000-01-27
NO20000414L true NO20000414L (en) 2000-03-28

Family

ID=25417733

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20000414A NO20000414L (en) 1997-07-31 2000-01-27 Benzyl compounds that inhibit leukocyte adhesion mediated by VLA-4

Country Status (12)

Country Link
EP (1) EP1001975A1 (en)
JP (1) JP2001512138A (en)
KR (1) KR20010022413A (en)
CN (1) CN1265675A (en)
AU (1) AU8585198A (en)
BR (1) BR9811573A (en)
CA (1) CA2291473A1 (en)
HU (1) HUP0002680A3 (en)
IL (1) IL133635A0 (en)
NO (1) NO20000414L (en)
PL (1) PL338510A1 (en)
WO (1) WO1999006436A1 (en)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6903075B1 (en) 1997-05-29 2005-06-07 Merck & Co., Inc. Heterocyclic amide compounds as cell adhesion inhibitors
DE69820614T2 (en) * 1997-05-30 2004-09-30 Celltech Therapeutics Ltd., Slough ANTI-INFLAMMATORY TYROSINE DERIVATIVES
GB2365338B (en) * 1997-06-14 2002-04-03 Enzacta R & D Ltd Therapeutic systems
PT991619E (en) 1997-06-23 2004-02-27 Upjohn Co INHIBITORS OF THE CELLULAR ADHESION MEDIATED BY ALFA4BETA1
US6423688B1 (en) 1997-07-31 2002-07-23 Athena Neurosciences, Inc. Dipeptide and related compounds which inhibit leukocyte adhesion mediated by VLA-4
US6559127B1 (en) 1997-07-31 2003-05-06 Athena Neurosciences, Inc. Compounds which inhibit leukocyte adhesion mediated by VLA-4
US7030114B1 (en) 1997-07-31 2006-04-18 Elan Pharmaceuticals, Inc. Compounds which inhibit leukocyte adhesion mediated by VLA-4
US6492421B1 (en) 1997-07-31 2002-12-10 Athena Neurosciences, Inc. Substituted phenylalanine type compounds which inhibit leukocyte adhesion mediated by VLA-4
US6583139B1 (en) 1997-07-31 2003-06-24 Eugene D. Thorsett Compounds which inhibit leukocyte adhesion mediated by VLA-4
US6939855B2 (en) 1997-07-31 2005-09-06 Elan Pharmaceuticals, Inc. Anti-inflammatory compositions and method
US6362341B1 (en) 1997-07-31 2002-03-26 Athena Neurosciences, Inc. Benzyl compounds which inhibit leukocyte adhesion mediated by VLA-4
US6489300B1 (en) 1997-07-31 2002-12-03 Eugene D. Thorsett Carbamyloxy compounds which inhibit leukocyte adhesion mediated by VLA-4
US6197794B1 (en) * 1998-01-08 2001-03-06 Celltech Therapeutics Limited Phenylalanine derivatives
MY153569A (en) 1998-01-20 2015-02-27 Mitsubishi Tanabe Pharma Corp Inhibitors of ?4 mediated cell adhesion
US6329372B1 (en) 1998-01-27 2001-12-11 Celltech Therapeutics Limited Phenylalanine derivatives
AU3260399A (en) 1998-02-26 1999-09-15 Celltech Therapeutics Limited Phenylalanine derivatives as inhibitors of alpha4 integrins
US6521626B1 (en) 1998-03-24 2003-02-18 Celltech R&D Limited Thiocarboxamide derivatives
GB9811159D0 (en) 1998-05-22 1998-07-22 Celltech Therapeutics Ltd Chemical compounds
GB9811969D0 (en) 1998-06-03 1998-07-29 Celltech Therapeutics Ltd Chemical compounds
US6685617B1 (en) 1998-06-23 2004-02-03 Pharmacia & Upjohn Company Inhibitors of α4β1 mediated cell adhesion
GB9814414D0 (en) 1998-07-03 1998-09-02 Celltech Therapeutics Ltd Chemical compounds
US6333340B1 (en) * 1998-08-14 2001-12-25 Gpi Nil Holdings, Inc. Small molecule sulfonamides for vision and memory disorders
US6339101B1 (en) * 1998-08-14 2002-01-15 Gpi Nil Holdings, Inc. N-linked sulfonamides of N-heterocyclic carboxylic acids or isosteres for vision and memory disorders
GB9919776D0 (en) * 1998-08-31 1999-10-27 Zeneca Ltd Compoujnds
GB9821061D0 (en) 1998-09-28 1998-11-18 Celltech Therapeutics Ltd Chemical compounds
GB9821222D0 (en) 1998-09-30 1998-11-25 Celltech Therapeutics Ltd Chemical compounds
GB9825652D0 (en) 1998-11-23 1999-01-13 Celltech Therapeutics Ltd Chemical compounds
GB9826174D0 (en) 1998-11-30 1999-01-20 Celltech Therapeutics Ltd Chemical compounds
US6407066B1 (en) 1999-01-26 2002-06-18 Elan Pharmaceuticals, Inc. Pyroglutamic acid derivatives and related compounds which inhibit leukocyte adhesion mediated by VLA-4
US6518283B1 (en) 1999-05-28 2003-02-11 Celltech R&D Limited Squaric acid derivatives
US6534513B1 (en) 1999-09-29 2003-03-18 Celltech R&D Limited Phenylalkanoic acid derivatives
DE60043308D1 (en) * 1999-12-16 2009-12-24 Biogen Idec Inc METHOD FOR TREATING THE INJURY OF THE CENTRAL NERVOUS SYSTEM BY ISCHEMIA OR BY HEMORRHAGIA WITH ANTAGONISTS OF ALPHA4 INTEGRIN
US6455539B2 (en) 1999-12-23 2002-09-24 Celltech R&D Limited Squaric acid derivates
HUP0203897A3 (en) 1999-12-28 2005-06-28 Pfizer Prod Inc Non-peptidyl inhibitors of vla-4 dependent cell binding useful in treating inflammatory, autoimmune, and respiratory diseases
JP2003531141A (en) 2000-04-17 2003-10-21 セルテック アール アンド ディ リミテッド Enamine derivatives
US6545013B2 (en) 2000-05-30 2003-04-08 Celltech R&D Limited 2,7-naphthyridine derivatives
US6403608B1 (en) 2000-05-30 2002-06-11 Celltech R&D, Ltd. 3-Substituted isoquinolin-1-yl derivatives
US6960597B2 (en) * 2000-06-30 2005-11-01 Orth-Mcneil Pharmaceutical, Inc. Aza-bridged-bicyclic amino acid derivatives as α4 integrin antagonists
EP1301488A1 (en) 2000-07-07 2003-04-16 Celltech R&D Limited Squaric acid derivatives containing a bicyclic heteroaromatic ring as integrin antagonists
AU2001275724A1 (en) 2000-08-02 2002-02-13 Celltech R&D Limited 3-substituted isoquinolin-1-yl derivatives
MY129000A (en) 2000-08-31 2007-03-30 Tanabe Seiyaku Co INHIBITORS OF a4 MEDIATED CELL ADHESION
JP2005022976A (en) * 2001-07-18 2005-01-27 Ajinomoto Co Inc Carboxylic acid derivative
MY140707A (en) 2002-02-28 2010-01-15 Mitsubishi Tanabe Pharma Corp Process for preparing a phenylalanine derivative and intermediates thereof
AU2003240757B2 (en) * 2002-03-28 2008-07-03 Merck Serono Sa Thiazolidine carboxamide derivatives as modulators of the prostaglandin F receptor
KR20050114212A (en) * 2003-01-24 2005-12-05 엘란 파마슈티칼스, 인크. Composition for and treatment of demyelinating diseases and paralysis by administration of remyelinating agents
EP1753421B1 (en) * 2004-04-20 2012-08-01 Amgen Inc. Arylsulfonamides and uses as hydroxysteroid dehydrogenase
JP4812758B2 (en) * 2004-06-29 2011-11-09 アベンティス・ファーマスーティカルズ・インコーポレイテツド FKBP binding composition and its pharmaceutical use
US20100150915A1 (en) 2007-02-20 2010-06-17 Stewart Edward J Methods of treating multiple sclerosis by administration of alpha-fetoprotein in combination with an integrin antagonist
MX2010011145A (en) 2008-04-11 2011-04-11 Merrimack Pharmaceuticals Inc Human serum albumin linkers and conjugates thereof.
PT2558499T (en) 2010-04-16 2017-07-14 Biogen Ma Inc Anti-vla-4 antibodies
CN102675244B (en) * 2011-03-16 2016-03-30 中国人民解放军军事医学科学院毒物药物研究所 Thiazine amide derivatives and in the purposes preparing neurodegenerative disease medicine
KR20170052526A (en) 2014-03-13 2017-05-12 프로테나 바이오사이언시즈 리미티드 Combination treatment for multiple sclerosis
US12037398B2 (en) 2018-06-04 2024-07-16 Biogen Ma Inc. Anti-VLA-4 antibodies having reduced effector function
WO2020092394A1 (en) 2018-10-30 2020-05-07 Gilead Sciences, Inc. Imidazopyridine derivatives as alpha4beta7 integrin inhibitors
PL3873605T3 (en) 2018-10-30 2025-03-03 Gilead Sciences, Inc. Compounds for inhibition of alpha4beta7 integrin
DK3873884T3 (en) 2018-10-30 2025-02-17 Gilead Sciences Inc 3-(QUINOLIN-8-YL)-1,4-DIHYDROPYRIDO[3,4-D]PYRIMIDINE-2,4-DIONE DERIVATIVES AS ALPHA4BETA7 INTEGRIN INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES
EP3873897B1 (en) 2018-10-30 2024-08-14 Gilead Sciences, Inc. N-benzoyl-phenylalanine derivatives as alpha4beta7 integrin inhibitors for treating inflammatory diseases
US11578069B2 (en) 2019-08-14 2023-02-14 Gilead Sciences, Inc. Compounds for inhibition of α4 β7 integrin

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04154732A (en) * 1990-10-18 1992-05-27 Nippon Kayaku Co Ltd Optical resolution method
WO1995015973A1 (en) * 1993-12-06 1995-06-15 Cytel Corporation Cs-1 peptidomimetics, compositions and methods of using the same
US6306840B1 (en) * 1995-01-23 2001-10-23 Biogen, Inc. Cell adhesion inhibitors

Also Published As

Publication number Publication date
HUP0002680A2 (en) 2001-07-30
PL338510A1 (en) 2000-11-06
HUP0002680A3 (en) 2001-12-28
BR9811573A (en) 2000-09-19
CN1265675A (en) 2000-09-06
AU8585198A (en) 1999-02-22
CA2291473A1 (en) 1999-02-11
IL133635A0 (en) 2001-04-30
EP1001975A1 (en) 2000-05-24
WO1999006436A1 (en) 1999-02-11
NO20000414D0 (en) 2000-01-27
KR20010022413A (en) 2001-03-15
JP2001512138A (en) 2001-08-21

Similar Documents

Publication Publication Date Title
NO20000414L (en) Benzyl compounds that inhibit leukocyte adhesion mediated by VLA-4
NO20000451L (en) Compounds that inhibit leukocyte adhesion mediated by VLA-4
NO20000412L (en) Dipeptide compounds that inhibit leukocyte adhesion mediated by VLA-4
NO20000452L (en) Sulfonylated dipeptide compounds that inhibit leukocyte adhesion mediated by VLA-4
NO20000413L (en) Carbamyloxy compounds that inhibit leukocyte adhesion mediated by VLA-4
NO20000410L (en) Dipeptide and related compounds that inhibit leukocyte adhesion mediated by VLA-4
NO20000411L (en) 4-Amino-phenylalamine compounds that inhibit leukocyte adhesion mediated by VLA-4
NO20000450L (en) Substituted phenylalanine compounds that inhibit leukocyte adhesion mediated by VLA-4
MXPA01007335A (en) Acyl derivatives which treat vla-4 related disorders.
NO20082002L (en) Pyrimidinylamide compounds that inhibit leukocyte adhesion mediated by VLA-4
NO20070216L (en) Multivalent VLA-1 antagonists containing polymer halves
NO20043900L (en) Heterocyclic compounds that inhibit leukocyte adhesion mediated by integrins
WO2000043354A3 (en) Multicyclic compounds which inhibit leukocyte adhesion mediated by vla-4
NO20083743L (en) Pyrimidinylsulfonamide Compounds That Inhibit Leukocyte Adhesion Mediated by VLA-4
EA200401561A1 (en) HETEROARRYLIC COMPOUNDS THAT INHIBIT MEDIATED ГР4-INTEGRINES leukocyte adhesion
WO2002008203A3 (en) 3-(heteroaryl) alanine derivatives-inhibitors of leukocyte adhesion mediated by vla-4
AU3246600A (en) Alpha-aminoacetic acid derivatives useful as alpha 4 beta 7 receptor antagonists
WO2002008201A3 (en) Beta-amino acid derivatives-inhibitors of leukocyte adhesion mediated by vla-4
WO2000043371A3 (en) Fused ring heteroaryl and heterocyclic compounds which inhibit leukocyte adhesion mediated by vla-4
WO2000043413A3 (en) Pyroglutamic acid derivatives and related compounds which inhibit leukocyte adhesion mediated by vla-4
ZA200803016B (en) Carbamate compounds which inhibit leukocyte adhesion mediated by VLA-4

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application